ATE478872T1 - Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung - Google Patents

Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung

Info

Publication number: ATE478872T1
Authority: AT; Austria
Prior art keywords: alkyl; group; cycloalkyl; optionally substituted; alkenyl
Prior art date: 2002-03-28

Application number

AT02007163T

Other languages

English (en)

Inventor

Daniela Moravcova

Libor Havlicek

Vladimir Krystof

Rene Lenobel

Miroslav Strnad

Original Assignee

Ustav Ex Botan Av Cr V V I I O

Univerzita Palackeho V Olomouc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-28

Filing date

2002-03-28

Publication date

2010-09-15

2002-03-28 Application filed by Ustav Ex Botan Av Cr V V I I O, Univerzita Palackeho V Olomouc filed Critical Ustav Ex Botan Av Cr V V I I O

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE478872T1 publication Critical patent/ATE478872T1/de

Links

230000001225 therapeutic effect Effects 0.000 title 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
125000006193 alkinyl group Chemical group 0.000 abstract 5
125000000753 cycloalkyl group Chemical group 0.000 abstract 5
125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 3
125000003118 aryl group Chemical group 0.000 abstract 3
-1 cycloheteroalkyl Chemical group 0.000 abstract 3
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
125000003710 aryl alkyl group Chemical group 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000003282 alkyl amino group Chemical group 0.000 abstract 1
125000002877 alkyl aryl group Chemical group 0.000 abstract 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
125000004404 heteroalkyl group Chemical group 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Dermatology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Transplantation (AREA)

AT02007163T 2002-03-28 2002-03-28 Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung ATE478872T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP02007163A EP1348707B1 (de)	2002-03-28	2002-03-28	Pyrazolo[4,3-d]pyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung

Publications (1)

Publication Number	Publication Date
ATE478872T1 true ATE478872T1 (de)	2010-09-15

Family

ID=27798825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02007163T ATE478872T1 (de)	2002-03-28	2002-03-28	Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung

Country Status (9)

Country	Link
US (1)	US7745450B2 (de)
EP (1)	EP1348707B1 (de)
JP (1)	JP2005527565A (de)
AT (1)	ATE478872T1 (de)
AU (1)	AU2003226731B2 (de)
CA (1)	CA2480409C (de)
DE (1)	DE60237425D1 (de)
DK (1)	DK1348707T3 (de)
WO (1)	WO2003082872A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050154046A1 (en) *	2004-01-12	2005-07-14	Longgui Wang	Methods of treating an inflammatory-related disease
EA008596B1 (ru)	2003-04-29	2007-06-29	Пфайзер Инк.	5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
WO2005012256A1 (en)	2003-07-22	2005-02-10	Astex Therapeutics Limited	3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
GB0327323D0 (en) *	2003-11-24	2003-12-31	Pfizer Ltd	Novel pharmaceuticals
GB0327319D0 (en) *	2003-11-24	2003-12-24	Pfizer Ltd	Novel pharmaceuticals
US7572799B2 (en)	2003-11-24	2009-08-11	Pfizer Inc	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
AU2004309420B2 (en) *	2003-12-23	2008-10-30	Novartis Ag	Bicyclic heterocyclic p-38 kinase inhibitors
DK1742950T3 (da)	2004-04-07	2009-03-16	Pfizer Ltd	Pyrazolo-[4,3-D]-pyrimidiner
WO2005118588A1 (ja) *	2004-06-02	2005-12-15	Takeda Pharmaceutical Company Limited	縮合複素環化合物
US7745446B2 (en)	2004-09-06	2010-06-29	Bayer Schering Pharma Aktiengesellschaft	Pyrazolo[1,5-c]pyrimidines
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
AR054425A1 (es)	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
RU2425677C2 (ru) *	2005-01-21	2011-08-10	Астекс Терапьютикс Лимитед	Соединения, предназначенные для использования в фармацевтике
CA2608018C (en) *	2005-05-12	2010-07-13	Pfizer Inc.	Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
US7932257B2 (en)	2005-07-22	2011-04-26	Sunesis Pharmaceuticals, Inc.	Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
NL2000291C2 (nl)	2005-11-10	2009-02-17	Pfizer Prod Inc	1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
FR2899107B1 (fr) *	2006-03-30	2008-06-13	Neurokin Entpr Unipersonnelle	Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
BRPI0720169A2 (pt)	2006-12-12	2013-12-24	Takeda Pharmaceutical	Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
US20090099195A1 (en) *	2007-05-08	2009-04-16	Astrazeneca Ab	Therapeutic Compounds 570
UA103195C2 (uk)	2008-08-11	2013-09-25	Глаксосмитклайн Ллк	Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
MX2011004680A (es)	2008-11-06	2011-05-25	Astrazeneca Ab	Moduladores de beta amiloide.
CZ2009358A3 (cs) *	2009-06-03	2010-12-15	C3 Bio Gmbh	5,7-Disubstituované 3-isopropylpyrazolo[4,3-d]pyrimidiny pro použití jako lécivo a farmaceutické prípravky tyto látky obsahující
CZ302711B6 (cs) *	2009-06-03	2011-09-14	Univerzita Palackého v Olomouci	Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující
AU2012244550C1 (en) *	2011-04-21	2017-06-22	Origenis Gmbh	Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
AU2012289042A1 (en)	2011-07-22	2014-03-13	Glaxosmithkline Llc	Composition
AR090650A1 (es) *	2012-04-12	2014-11-26	Alcon Res Ltd	Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
MX359671B (es)	2012-08-24	2018-10-05	Glaxosmithkline Llc Star	Compuestos de pirazolopiridina.
US9637491B2 (en)	2012-10-19	2017-05-02	Origenis Gmbh	Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
PL2922549T3 (pl)	2012-11-20	2017-11-30	Glaxosmithkline Llc	Nowe związki
WO2014081643A1 (en)	2012-11-20	2014-05-30	Glaxosmithkline Llc	Novel compounds
CA2890201A1 (en)	2012-11-20	2014-05-30	Glaxosmithkline Llc	Novel compounds
CN103405439B (zh) *	2013-08-02	2014-12-31	上海市第十人民医院	嘧啶类化合物在制备真菌药物的应用
WO2016145488A1 (en) *	2015-03-16	2016-09-22	Monash University	Treatment of skin conditions
CZ307147B6 (cs) *	2015-05-14	2018-02-07	Ústav experimentální botaniky AV ČR, v. v. i.	5-Substituované 7-[4-(2-pyridyl)fenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako léčiva, a farmaceutické přípravky
US10174039B2 (en) *	2016-09-30	2019-01-08	Asana Biosciences, Llc	P2X3 and/or P2X2/3 compounds and methods
CZ308484B6 (cs) *	2018-02-05	2020-09-16	Univerzita PalackĂ©ho v Olomouci	5-Alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidiny pro léčení lymfomů
EP3797776B1 (de) *	2019-09-30	2025-07-23	Universitätsmedizin Mainz	Cdk4/6-hemmer zur behandlung von psoriasis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3988338A (en) *	1974-04-24	1976-10-26	Wisconsin Alumni Research Foundation	4-Substituted amino-2-substituted thio-pyrrolo-[2,3-d]pyrimidine derivatives
GB9013750D0 (en) *	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
US5276143A (en)	1990-12-21	1994-01-04	E. I. Du Pont De Nemours And Company	Dideoxyfructonucleosides and deoxyfructonucleotides
US5801015A (en)	1995-06-05	1998-09-01	Mitotix, Inc.	Nucleic acid encoding a Candida cell cycle regulatory protein, TYP1 polypeptide
US6200980B1 (en)	1995-06-07	2001-03-13	Cell Pathways, Inc.	Method of treating a patient having precancerous lesions with phenyl purinone derivatives
EP0778277B1 (de) *	1995-12-08	2003-06-25	Pfizer Inc.	Substitutierte heterozyclische Derivate als CRF Antagonisten
TR199900389T2 (xx) *	1996-08-28	2000-06-21	Pfizer Inc.	�kame edilmi� 6,5-hetero-bisiklik t�revleri.
US5723608A (en) *	1996-12-31	1998-03-03	Neurogen Corporation	3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
SK285991B6 (sk) *	1997-04-25	2008-01-07	Pfizer Inc.	Pyrazolopyrimidinóny, spôsob a medziprodukty na ich výrobu, ich použitie a farmaceutické a veterinárne kompozície na ich báze
US5985848A (en) *	1997-10-14	1999-11-16	Albert Einstein College Of Medicine Of Yeshiva University	Inhibitors of nucleoside metabolism
EP1371647B1 (de) *	1998-04-20	2005-07-13	Pfizer Inc.	Pyridin-3-carbonsäurederivate und ihre Verwendung als Zwischenprodukte
DE69911448T2 (de) *	1998-10-23	2004-04-08	Pfizer Inc.	Pyrazolopyrimidinone, cgmp pde5 inhibitoren, zur behandlung von sexuellen funktionsstörungen
AU1888800A (en) *	1999-09-13	2001-04-17	Cipla Limited	A novel process for the synthesis of sildenafil citrate
AU779761C (en) *	1999-10-12	2005-09-22	Lilly Icos Llc	Medicament for treatment of neuropathies
DE10060388A1 (de) *	2000-12-05	2002-06-06	Merck Patent Gmbh	Verwendung von Pyrazolo [4,3-d]pyrimidinen
CA2431077A1 (en) *	2000-12-19	2002-06-27	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
GB0106661D0 (en) *	2001-03-16	2001-05-09	Pfizer Ltd	Pharmaceutically active compounds
JP2005508978A (ja) *	2001-11-02	2005-04-07	ファイザー・プロダクツ・インク	Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
US20030195205A1 (en) *	2001-11-02	2003-10-16	Pfizer Inc.	PDE9 inhibitors for treating cardiovascular disorders

2002
- 2002-03-28 AT AT02007163T patent/ATE478872T1/de not_active IP Right Cessation
- 2002-03-28 DE DE60237425T patent/DE60237425D1/de not_active Expired - Lifetime
- 2002-03-28 EP EP02007163A patent/EP1348707B1/de not_active Expired - Lifetime
- 2002-03-28 DK DK02007163.5T patent/DK1348707T3/da active
2003
- 2003-03-27 CA CA2480409A patent/CA2480409C/en not_active Expired - Fee Related
- 2003-03-27 AU AU2003226731A patent/AU2003226731B2/en not_active Ceased
- 2003-03-27 JP JP2003580337A patent/JP2005527565A/ja active Pending
- 2003-03-27 WO PCT/EP2003/003207 patent/WO2003082872A1/en not_active Ceased
2004
- 2004-09-28 US US10/952,087 patent/US7745450B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DK1348707T3 (da)	2010-12-13
US20050080097A1 (en)	2005-04-14
EP1348707B1 (de)	2010-08-25
AU2003226731B2 (en)	2008-05-22
DE60237425D1 (de)	2010-10-07
US7745450B2 (en)	2010-06-29
JP2005527565A (ja)	2005-09-15
AU2003226731A1 (en)	2003-10-13
CA2480409C (en)	2010-06-22
EP1348707A1 (de)	2003-10-01
WO2003082872A1 (en)	2003-10-09
CA2480409A1 (en)	2003-10-09

Legal Events

Date	Code	Title	Description
2011-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60237425D1 (de)	2010-10-07	PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
CA2184919A1 (en)	1996-07-18	New Piperazine Derivatives and Methods for the Preparation Thereof and Compositions Containing the Same
CA2337041A1 (en)	2000-02-17	Aminomethylcarboxylic acid derivatives
WO2003076458A3 (en)	2003-11-06	Selective dipeptide inhibitors of kallikrein
CA2368413A1 (en)	2000-10-05	Derivatives of pyrimido[6,1-a]isoquinolin-4-one
HUP0301671A2 (hu)	2003-08-28	4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk
ATE225348T1 (de)	2002-10-15	Substituierte azaindolylidenderivate und verfahren zu ihrer herstellung
WO2005092858A3 (en)	2006-03-02	Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
SE0104332D0 (sv)	2001-12-19	Therapeutic agents
CA2534024A1 (en)	2005-02-10	Novel compounds having inhibitory activity against sodium-dependant transporter
MY141504A (en)	2010-05-14	Gamma secretase inhibitors
PT1159279E (pt)	2003-02-28	4-oxo-4,7-di-hidrotieno¬2,3-b\|piridino-5-carboxamidas como agentes antivirais
TW368501B (en)	1999-09-01	7-(2-aminoethyl)-benzothiazolones
TW235297B (de)	1994-12-01
JP2005538111A5 (de)	2006-08-31
CA2213080A1 (en)	1996-08-29	1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
EP2289888A3 (de)	2011-07-13	Epoxidcarboxylsäureamide, Azide und Aminoalkohole sowie Verfahren zur Herstellung von Alpha-Ketoamiden damit
MY138051A (en)	2009-04-30	Compounds and processes
TW200420559A (en)	2004-10-16	Amine compounds and method for producing the same
AR023914A1 (es)	2002-09-04	Caprolactamas sustituidas, un proceso para su preparacion, composiciones farmaceuticas que las contienen, y su uso para la preparacion de composicionesfarmaceuticas en el tratamiento de tumores
EP0431520A3 (en)	1992-06-03	Heterocyclic acyl aminodiol beta-amino acid derivatives
DE50202381D1 (de)	2005-04-07	Geschützte tyrosinderivate, verfahren zu deren herstellung und deren verwendung zur herstellung von o-(2- ?18 f]-fluorethyl)-l-tyrosin
GB0113232D0 (en)	2001-07-25	Chemical process
MXPA01009768A (es)	2004-08-12	Analogos de fenoxazina utiles como inhibidores de la agregacion amiloide y para el tratamiento de la enfermedad de alzheimer y las enfermedades relacionadas con la amiloidosis.
TW200510300A (en)	2005-03-16	Amino alcohol compounds